key: cord-0062653-qe4e7oju
authors: Elstein, Jack; Gilfix, Reisa; Elstein, Eleanor
title: How Did Elderly T2D Patients Cope With the Quebec Covid-19 Lockdown
date: 2021-05-03
journal: J Endocr Soc
DOI: 10.1210/jendso/bvab048.698
sha: 370e638218af0b47afb6350d0fa1539aaf051b5e
doc_id: 62653
cord_uid: qe4e7oju

The Canadian city most affected by the first wave of the Covid-19 (CV19) pandemic was Montreal. Montreal was in lockdown (LD) from Mar 13- Jun 15, 2020. The elderly, diabetics, and the economically disadvantaged are among the groups most at risk of CV19 and the psychosocial effects of LD. We sought to ascertain the effect of the LD on the wellbeing of lower income elderly T2D pts. As we felt it unethical to do non-essential testing during a pandemic we relied on clinically available HbA1c’s as surrogates for metabolic wellbeing. Most HbA1c‘s used reflect a high (r=0.91) correlation with 3 month values for the time periods of interest. The study group was composed of 38 mostly elderly T2D pts. All pts lived alone or with similarly aged spouses in non-institutional settings in a lower middle class neighborhood of Montreal. None had organized domestic help from family or the community. None had documented acute medical episodes or medication changes between Jan and Sept 2020. None have conditions known to render HbA1c non reliable. Pts were interviewed by telephone to assess their overall coping with the LD. In particular they were questioned about medical issues, difficulties obtaining medications +/- groceries and psychological or social stress. HbA1c values between Jan 1 - Mar 15, 2020 and after Aug 25, 2020 (non LD values) and between Apr 20 - Aug 15, 2020 (LD values) were recorded. Differences in the recorded non LD and LD HbA1c’s were compared and analyzed for the group as a whole, by gender, and by insulin use. There were 38 pts, 22 M 56–77 yrs (mean 72.1) and 16 F 41–90 yrs (mean 75.2), 89.5% (34/38) were > 65 yrs. Ten M and 9 F were on insulin. No pt reported severe hypoglycemia or weight fluctuations. All claimed to be following public health guidelines. There were no significant differences (d) between the mean HbA1c’s non LD compared to LD neither for the entire group (d= 0.2), M (d=0.2), F (d=0.2), insulin treated pts (d=0.3) nor those not treated with insulin (d=0.0). There were no overt medical decompensations. No pt reported having been unable to access medications or groceries. No pt reported significant psychological distress or feelings of isolation. None had been diagnosed with CV19. This largely geriatric T2D cohort did not report any overt deleterious effects from the LD. There were no significant differences in HbA1c non LD compared to LD. It is not possible to determine how effective the LD was in protecting these pts from CV19 other than to note that none had been diagnosed as having contracted the disease. As the 2nd wave of CV19 evolves, health care professionals will have the opportunity to study the effect of public health interventions, not only on controlling the spread of CV19, but also on the general wellbeing of different pt populations.

Abstract: India is home to 77 million people with diabetes and has a large number of COVID 19 cases, albeit with a low fatality (<1.5%). Little Indian data is available about the prevalence of diabetes in COVID 19 and its impact on outcomes. This observational prospective study (approved by the Institutional Ethics Committee) was carried out in a designated COVID facility, largely catering to middle and upper socioeconomic classes. A total of 401 (125 F, mean age 54 y, range 19-92 y) consecutive adults hospitalized with COVID-19 infection as proven by positive nasal swab for SARS-CoV2 by RT-PCR were included. Diabetes mellitus was diagnosed either by known history or HbA1c≥6.5%. Severity was assessed using the WHO ordinal scale 1 . Clinical outcomes and markers of inflammation were compared between diabetes and non-diabetes groups. Out of 401 patients, 210 (52.4%) had either diabetes (189,47.1%) or hyperglycemia requiring insulin treatment (21, 5.2%). 152 (37.9%) reported known diabetes, and 37 (9.2%) had preexisting but undiagnosed diabetes (HbA1c≥ 6.5%). People with diabetes were significantly older (mean age 59.9 vs 47.7 y), and had a higher proportion of men (74.6 vs 63.7 %), hypertension (58.7 vs 25%), CAD (13.8 vs 4.2%), and CKD (5.3 vs 0.9%) and a higher mean baseline severity score (3.4±0.7 vs. 3.2±0.5, p-0.000). The diabetes group had a higher number of severe cases (WHO scale≥5) (20.1% vs 9%, p-0.002) and higher mortality (6.3 vs 1.4%, p-0.015). A higher proportion of the diabetes group required ICU admissions (24.3 vs 12.3%, p-0.002), glucocorticoid therapy (78.3 vs 54.2%, p-0.000), oxygen administration (53.4 vs 28.3%, p-0.000), inotropic support (7.4 vs 2.4%, p-0.019), and renal replacement therapy (3.7% vs 0,p-0.005). The mean duration of hospital stay was higher for the diabetes group (10.4 vs 9.1 days, p-0.016). Of those who died, 12/15 (80%) had diabetes. Baseline Hba1c (n=331) showed a significant correlation with outcome severity scores (r 0.136, p-0.013). Markers of inflammatory response, CRP (41.0±4.4 vs. 19.4±3.8, p-0.000), ferritin (404.8±41.6 vs. 258.8±40.2, p-0.012), IL6 (65.5±11.6 vs. 26.9±4.4, p-0.002), LDH (321.8±10.1 vs. 286.8±8.4, p-0.008) were significantly higher in the diabetes group. Procalcitonin and D Dimer did not differ significantly. In conclusion, we report the highest prevalence of diabetes in a hospitalized COVID-19 population so far. The diabetes group had more severe disease and greater mortality. Baseline HbA1c correlated with poor outcomes. The comorbidities could have contributed to these poorer outcomes in the diabetes group. Strategies to improve outcomes in this pandemic it is imperative to include screening for and better control of diabetes. Reference: 1 https://www.who.int/blueprint/prioritydiseases/key-action/COVID-19_Treatment_Trial_Design_ Master_Protocol_synopsis_Final_18022020.pdf The Canadian city most affected by the first wave of the Covid-19 (CV19) pandemic was Montreal. Montreal was in lockdown (LD) from Mar 13-Jun 15, 2020. The elderly, diabetics, and the economically disadvantaged are among the groups most at risk of CV19 and the psychosocial effects of LD. We sought to ascertain the effect of the LD on the wellbeing of lower income elderly T2D pts. As we felt it unethical to do non-essential testing during a pandemic we relied on clinically available HbA1c's as surrogates for metabolic wellbeing. Most HbA1c's used reflect a high (r=0.91) correlation with 3 month values for the time periods of interest. The study group was composed of 38 mostly elderly T2D pts. All pts lived alone or with similarly aged spouses in non-institutional settings in a lower middle class neighborhood of Montreal. None had organized domestic help from family or the community. None had documented acute medical episodes or medication changes between Jan and Sept 2020. None have conditions known to render HbA1c non reliable. Pts were interviewed by telephone to assess their overall coping with the LD. In particular they were questioned about medical issues, difficulties obtaining medications +/-groceries and psychological or social stress. HbA1c values between Jan 1 -Mar 15, 2020 and after Aug 25, 2020 (non LD values) and between Apr 20 -Aug 15, 2020 (LD values) were recorded. Differences in the recorded non LD and LD HbA1c's were compared and analyzed for the group as a whole, by gender, and by insulin use. There were 38 pts, 22 M 56-77 yrs (mean 72.1) and 16 F 41-90 yrs (mean 75.2), 89.5% (34/38) were > 65 yrs. Ten M and 9 F were on insulin. No pt reported severe hypoglycemia or weight fluctuations. All claimed to be following public health guidelines. There were no significant differences (d) between the mean HbA1c's non LD compared to LD neither for the entire group (d= 0.2), M (d=0.2), F (d=0.2), insulin treated pts (d=0.3) nor those not treated with insulin doi: 10.1210/jendso/bvab048 | Journal of the Endocrine Society | A343 J Endocrine Soc, Volume 5, Issue Supplement_1, April-May 2021 (d=0.0). There were no overt medical decompensations. No pt reported having been unable to access medications or groceries. No pt reported significant psychological distress or feelings of isolation. None had been diagnosed with CV19. This largely geriatric T2D cohort did not report any overt deleterious effects from the LD. There were no significant differences in HbA1c non LD compared to LD. It is not possible to determine how effective the LD was in protecting these pts from CV19 other than to note that none had been diagnosed as having contracted the disease. As the 2nd wave of CV19 evolves, health care professionals will have the opportunity to study the effect of public health interventions, not only on controlling the spread of CV19, but also on the general wellbeing of different pt populations. Background: Diabetes Mellitus is a factor for the development of micronagiopathies, it is well known at the level of retina, renal and peripheral nervous system. However, it is important to mention that high levels of glucose have deleterious effects on the walls of the vessels, causing microangiopathic damage to the lung, consequently this leads to pulmonary dysfunction. There is local oxidative stress, increased vascular permeability, producing changes in the secretion of the mucus that leads to reduced lung volumes, lung diffusion capacity, decrease bronchodilation. Knowing this complication at the pulmonary level derived from poor control of Diabetes Mellitus, diabetic pulmonary microangiopathy represents a challenge for the COVID-19 pandemic. There is a high prevalence of diabetic patients hospitalized for COVID-19 and the complications derived from this, that is why the idea arose to carry out this review and evaluate the impact that admission glucose levels have on the clinical evolution and prognosis of these patients. Elevated serum glucose levels have deleterious effects on the walls of blood vessels, leading to microangiopathy. Such a destructive process also involves the pulmonary circulation, where it is known as diabetic pulmonary microangiopathy. This hypothesis has been confirmed in histopathological examinations of the lung parenchyma, as well as in lung function tests. However, until now there have been no clinical implications of these findings. 1 Histopathological evidence of pulmonary involvement in subjects with diabetes mellitus has included thickened pulmonary capillary basal plates and alveolar epithelial plates, the latter suggesting existing pulmonary microangiopathy. Abnormal lung function has been detected in some diabetic patients. Glycosylation-induced non-enzymatic alteration of lung connective tissue is the most likely pathogenetic mechanism underlying mechanical lung dysfunction in diabetic subjects. while the most sustainable explanation for altered pulmonary microangiopathy. 2 Metodos: This short review looks at the main findings, prospective cross-sectional analytical study, in Guatemala Central America that included 319 patients with COVID 19, hospitalized with comorbidities like type 2 Diabetes Mellitus, hypertension and chronic kidney disease as medical history. These patients did not have a history of pulmonary pathology and who required a low-and high-flow oxygen device since admission, presenting moderate and severe COVID-19. These laboratories were carried out in the first chemistry performed after the onset of respiratory symptoms in the arrival at the hospital. Chi square was used for categorical variables and t student for numeric variables for the rest of the variables. Results: The study showed that in the severe group of patients the median age was 52 years old and in the moderate group it was 51. In the severe group of patients, a male gender predominance with 50.7% and 49.3% in moderate; showing the female sex 46% and 53% respectively. Regarding glucose levels at admission, there was a mean of 189mg / dl for severe patients and 156 mg / dl in moderate patients, with a P: 0.021. Conclusion: The primary point in this study is to see how the correlation was measured since they had to be two numerical variables for it to be correlation. In this case, blood glucose and vascular damage, the most severe cases were related to blood glucose levels greater than 125 mg/dl. In our study, we conclude that the presence of glycemic levels below 125 mg/dl is a protective factor with respect to mortality with an OR 0.521 (CL 0.324-0.835, Po.007). That means, that those patients who are admitted with glycemic levels greater than 126 mg/d have twice the risk to die at 28 days of admission than those who do not have levels greater than 125mg/dl. In the same way, those patients who were admitted with less than 95% saturation were compared and there was no significant difference p0.822) .

Krzysztof Kuziemski et al ¿Es el pulmón un "órgano diana" en la diabetes mellitus?

Hyperglycemia Is Associated With Increased Mortality in Critically Ill Patients With